Vertex Pharmaceuticals Incorporated
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| VRTX.VI | 095700.KQ | CSL.AX | KRYS | ROIV | 1530.HK | |
|---|---|---|---|---|---|---|
| Market cap | 117.25B | 111.88B | 94.12B | 9.52B | 27.43B | 33.76B |
| P/E (TTM) | 31.7 | — | — | 40.3 | — | 3.7 |
| Forward P/E | — | — | 20.6 | 35.9 | -22.1 | 10.0 |
| Price/book | 6.5 | — | 4.4 | 7.0 | 6.5 | 1.1 |
| Dividend yield | — | — | 2.07% | — | — | 1.75% |
| 1-year change | +22.99% | −51.15% | −11.16% | +72.79% | +103.09% | −47.31% |
| Today | +1.66% | −3.15% | +0.03% | −0.14% | +3.21% | −4.62% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All VRTX.VI news ›AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Choosing between established dividend payers and high-growth innovators is a classic investor dilemma. This comparison pits AbbVie (ABBV +2.26%) against Vertex Pharmaceuticals (VRTX +2.53%) to determine which company offers the best…
Vertex Pharmaceuticals (VRTX) Stock
Based on 9 analyst ratings The market is expecting earnings per share of $4.35 for this quarter. The company has not yet shared when it is announcing earnings. News tone: automated (AI) classification of the article's content, not a price…
Vertex Pharmaceuticals’ New Drugs Are Gaining Ground. Is That Enough for Investors?
Vertex is generating double-digit revenue growth, but with cystic fibrosis still contributing 96% of sales, its premium valuation puts the spotlight on diversification and future earnings. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)…
Vertex Pharmaceuticals Incorporated Announces Appointment of Daniel Brennan as Member of the Board of Directors, Audit and Finance Committee
On October 20, 2026, Daniel Brennan was appointed as a new member of the board of directors of Vertex Pharmaceuticals Incorporated . In connection with the appointment of Mr. Brennan, the size of the... On October 20, 2026, Daniel Brennan…
Lobbying Update: $1,100,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed
$1,100,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed, from Q3 of 2026, in a new Lobbying Disclosure Act filing. Members of Congress have traded $VRTX stock 1 times in the past 6 months. Of those trades, 0 have been…
Vertex Sets November 4 Date for Third-Quarter Earnings
KING OF PRUSSIA, PA — Vertex Inc. (Nasdaq: VERX), a provider of enterprise tax compliance software, will report its third-quarter 2026 financial results after the U.S. stock market closes on Wednesday, November 4, giving investors an…
Vertex Appoints Daniel Brennan to its Board of Directors
BioSpace Vertex Appoints Daniel Brennan to its Board of Directors BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Daniel Brennan has been appointed to its Board of Directors as an…
Why Should You Think About Vertex Differently Now?
Vertex Now Talks Up Medicines Beyond Cystic Fibrosis During its fiscal Q2 2026 call in August, management said the emerging renal franchise could one day rival CF in revenue. Executives also made the case for an agreement to acquire…
3,678 Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Banque Pictet & Cie SA
Posted by Defense World Staff on Oct 17th, 2026 NASDAQ:VRTX opened at $499.74 on Friday. The stock’s fifty day moving average is $523.54 and its 200 day moving average is $480.55. Vertex Pharmaceuticals Incorporated has a fifty-two week…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketscreener.com17
-
fool.com7
-
theglobeandmail.com4
-
defenseworld.net3
-
themarketsdaily.com3
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 65 articles, not a forecast.